[
  {
    "ts": null,
    "headline": "DexCom Stock: Analyst Estimates & Ratings",
    "summary": "Despite DexCom’s underwhelming price action, Wall Street analysts appear highly optimistic about its prospects.",
    "url": "https://finnhub.io/api/news?id=8ad387f814daebd2e0f47b0bca4d07813f8e140cc59b51ca45c2b6a702606acc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755187986,
      "headline": "DexCom Stock: Analyst Estimates & Ratings",
      "id": 136349747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Despite DexCom’s underwhelming price action, Wall Street analysts appear highly optimistic about its prospects.",
      "url": "https://finnhub.io/api/news?id=8ad387f814daebd2e0f47b0bca4d07813f8e140cc59b51ca45c2b6a702606acc"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons We’re Fans of DexCom (DXCM)",
    "summary": "Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=5776f853b62e3658c584511f20bfa761f40a9dc779730b551822a8548f74d342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755144119,
      "headline": "3 Reasons We’re Fans of DexCom (DXCM)",
      "id": 136345079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=5776f853b62e3658c584511f20bfa761f40a9dc779730b551822a8548f74d342"
    }
  }
]